Plus Therapeutics Stock Investor Sentiment
| PSTV Stock | USD 0.63 0.05 7.40% |
Slightly above 58% of Plus Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Plus Therapeutics suggests that many traders are alarmed. Plus Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Plus Therapeutics' earnings reports, geopolitical events, and overall market trends.
Comfort Level 42
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Plus Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Plus Therapeutics.
News SentimentBearish | Hype SentimentBearish | Insider SentimentAcquiring |
Plus Historical Sentiment
Although Plus Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Plus, such as negative comments on social media and news outlets, may cause fear in the market and push Plus Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Plus.
Plus |
Plus Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Plus Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Plus Therapeutics Historical Investor Sentiment
Investor biases related to Plus Therapeutics' public news can be used to forecast risks associated with an investment in Plus. The trend in average sentiment can be used to explain how an investor holding Plus can time the market purely based on public headlines and social activities around Plus Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Plus Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Plus Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Plus Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Plus Therapeutics.
Far too much social signal, news, headlines, and media speculation about Plus Therapeutics that are available to investors today. That information is available publicly through Plus media outlets and privately through word of mouth or via Plus internal channels. However, regardless of the origin, that massive amount of Plus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Plus Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Plus Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Plus Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Plus Therapeutics alpha.
Plus Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Plus Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights - br.ADVFN.com | 02/13/2025 |
2 | Plus Therapeutics Secures 5.7 Million Financing to Support Leptomeningeal Metastases Program | 02/18/2025 |
3 | Plus Therapeutics Announces Leadership Appointments for itsCNSi | 02/24/2025 |
4 | Plus Therapeutics Advances Lead Drug Rhenium Obisbemeda for Patients with Leptomeningeal Metastases | 02/26/2025 |
5 | Acquisition by Andrew Sims of 1000 shares of Plus Therapeutics at 1.8643 subject to Rule 16b-3 | 02/28/2025 |
6 | Plus Therapeutics Secures Private Placement of Approximately 15 Million in Gross Proceeds | 03/04/2025 |
7 | Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium Obisbemeda for ... | 03/06/2025 |
8 | UT Health San Antonio develops drug found to more than double survival time for glioblastoma patients | 03/07/2025 |
9 | Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement | 03/10/2025 |
10 | Acquisition by Petersen Greg of 3650 shares of Plus Therapeutics at 1.26 subject to Rule 16b-3 | 03/12/2025 |
11 | Plus Therapeutics, Inc. Short Interest Up 134.4 percent in February | 03/13/2025 |
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.